keyword
MENU ▼
Read by QxMD icon Read
search

dutasteride

keyword
https://www.readbyqxmd.com/read/28338531/hormonal-manipulation-with-finasteride-or-oral-contraception-does-not-influence-incidence-of-renal-cell-carcinoma
#1
Aashish Kabra, Jonathan Gelfond, Michael A Liss
Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy...
March 23, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28319231/association-of-suicidality-and-depression-with-5%C3%AE-reductase-inhibitors
#2
Blayne Welk, Eric McArthur, Michael Ordon, Kelly K Anderson, Jade Hayward, Stephanie Dixon
Importance: There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective: To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement. Design, Setting, and Participants: A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 years or older (median [IQR] age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a 5α-reductase inhibitor during the study period (2003 through 2013)...
March 20, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28294070/dutasteride-in-androgenetic-alopecia-an-update
#3
Tasleem Arif, Konchok Dorjay, Mohammad Adil, Marwa Sami
BACKGROUND: Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-a-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5-alpha-reductase. Finasteride and minoxidil are the only approved drugs for androgenetic alopecia. Dutasteride has been demonstrated to be effective in several randomized, double-blind, placebo controlled trials in androgenetic alopecia...
March 10, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28289563/persistent-erectile-dysfunction-in-men-exposed-to-the-5%C3%AE-reductase-inhibitors-finasteride-or-dutasteride
#4
Tina Kiguradze, William H Temps, Paul R Yarnold, John Cashy, Robert E Brannigan, Beatrice Nardone, Giuseppe Micali, Dennis Paul West, Steven M Belknap
IMPORTANCE: Case reports describe persistent erectile dysfunction (PED) associated with exposure to 5α-reductase inhibitors (5α-RIs). Clinical trial reports and the manufacturers' full prescribing information (FPI) for finasteride and dutasteride state that risk of sexual adverse effects is not increased by longer duration of 5α-RI exposure and that sexual adverse effects of 5α-RIs resolve in men who discontinue exposure. OBJECTIVE: Our chief objective was to assess whether longer duration of 5α-RI exposure increases risk of PED, independent of age and other known risk factors...
2017: PeerJ
https://www.readbyqxmd.com/read/28261678/early-dutasteride-monotherapy-in-men-with-detectable-serum-prostate-specific-antigen-levels-following-radical-prostatectomy-a-prospective-trial
#5
Yu Seob Shin, Jea Whan Lee, Myung Ki Kim, Young Beom Jeong, Seung Chol Park
PURPOSE: To investigate the effects of early administration of dutasteride in patients with detectable serum prostate-specific antigen (PSA) levels after radical prostatectomy (RP). MATERIALS AND METHODS: A prospective open-label study, with a cumulative analysis of asymptomatic increase in PSA following RP, was conducted from January 2005 to December 2013. An early increase in PSA level was defined as detectable serum PSA level> 0.04 ng/mL. Patients with PSA level>0...
March 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28257560/dutasteride-add-on-therapy-reduces-detrusor-mass-in-patients-with-benign-prostatic-enlargement-not-satisfied-with-alpha-adrenergic-antagonist-monotherapy-a-single-center-prospective-study
#6
Cosimo De Nunzio, Aldo Brassetti, Flavia Proietti, Mauro Gacci, Sergio Serni, Francesco Esperto, Andrea Tubaro
AIMS: The ultrasound assessment of bladder wall thickness (BWT) and intravesical prostatic protrusion (IPP) have emerged as a non-invasive, inexpensive, time-saving alternatives to pressure-flow studies to assess benign prostatic obstruction (BPO). Aim of our study was to evaluate the effect on detrusor mass of dutasteride add-on therapy in men with lower urinary tract symptoms (LUTS) and benign prostatic enlargement (BPE). METHODS: A consecutive series of BPE patients with a prostate volume (PV) ≥30 mL and an international prostate symptoms score (IPSS) ≥8 not satisfied with Tamsulosin monotherapy were enrolled...
March 3, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28228662/risk-of-gynecomastia-and-breast-cancer-associated-with-the-use-of-5-alpha-reductase-inhibitors-for-benign-prostatic-hyperplasia
#7
Katrina Wilcox Hagberg, Hozefa A Divan, Shona C Fang, J Curtis Nickel, Susan S Jick
BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study with nested case-control analyses using the UK Clinical Practice Research Datalink. We identified men diagnosed with BPH who were free from Klinefelter syndrome, prostate, genital or urinary cancer, prostatectomy or orchiectomy, or evidence of gynecomastia or breast cancer...
2017: Clinical Epidemiology
https://www.readbyqxmd.com/read/28208224/percent-decrease-of-serum-prostate-specific-antigen-after-dutasteride-administration-is-equivalent-in-men-with-clinical-benign-prostatic-hyperplasia-having-baseline-prostate-specific-antigen-10-ng-ml-and-those-having-baseline-prostate-specific-antigen-2-5-10
#8
Hideki Takeshita, Satoru Kawakami, Akihiro Yano, Yohei Okada, Makoto Morozumi, Takumi Yamada
No abstract text is available yet for this article.
February 16, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28151719/neoadjuvant-enzalutamide-prior-to-prostatectomy
#9
Bruce Montgomery, Maria S Tretiakova, Anthony M Joshua, Martin E Gleave, Neil Fleshner, Glenn J Bubley, Elahe A Mostaghel, Kim N Chi, Daniel W Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W Kantoff, Brett T Marck, Stephen Plymate, Steven P Balk, Peter S Nelson, Alvin M Matsumoto, Rosina T Lis, Adam Kibel, Gabriel P Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin
Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride (dut) and leuprolide (enza/dut/luteinizing hormone-releasing hormone analogues [LHRHa]).Experimental Design: Forty-eight of 52 men with intermediate or high-risk localized prostate cancer proceeded to prostatectomy after neoadjuvant enzalutamide or enza/dut/LHRHa for 6 months...
November 9, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28145028/effects-of-steroidal-antiandrogen-or-5-alpha-reductase-inhibitor-on-prostate-tissue-hormone-content
#10
Yasuhiro Shibata, Seiji Arai, Yoshiyuki Miyazawa, Takahiro Shuto, Masashi Nomura, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Kazuto Ito, Kazuhiro Suzuki
BACKGROUND: The effects of a steroidal antiandrogen (AA) and 5-alpha-reductase inhibitor (5ARI) on prostate tissue hormone content and metabolism are not fully elucidated. The objective of this study is to investigate the hormone content and metabolism of the prostate tissues of patients treated with AA or 5ARI using the ultra-sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. METHODS: Thirty-nine patients with benign prostatic hyperplasia (BPH) undergoing transurethral surgery were included...
February 1, 2017: Prostate
https://www.readbyqxmd.com/read/28127948/bioequivalence-studies-of-a-reformulated-dutasteride-and-tamsulosin-hydrochloride-combination-capsule-and-a-commercially-available-formulation
#11
Renee Kurczewski, Chet Bowen, David Collins, John Zhu, Gulyeter Serbest, Michael Manyak
A dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg combination (DTC) capsule (Duodart(®) ) was reformulated to reduce the capsule size and enhance product stability. Bioequivalence of the reformulated DTC capsule with the commercial formulation was evaluated in 2 single-dose, open-label, randomized, 2-way crossover studies in healthy adult male volunteers. Subjects in a fasted or fed state received a single oral dose of either the reformulated DTC or the commercial formulation followed by a 28-day washout period between treatments...
January 27, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28102554/what-are-the-predicting-factors-for-the-therapeutic-effects-of-dutasteride-in-male-patients-with-lower-urinary-tract-symptoms-investigation-using-a-urodynamic-study
#12
Yoshihisa Matsukawa, Masashi Kato, Yasuhito Funahashi, Tsuyoshi Majima, Tokunori Yamamoto, Momokazu Gotoh
AIMS: We investigated predicting factors for the therapeutic effects of dutasteride in patients with lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) based on a urodynamic study (UDS). METHODS: This was a single-center, prospective study involving 120 male outpatients with LUTS. They received 0.5 mg of dutasteride per day for 12 months. IPSS, OABSS, IPSS-QOL, and UDS were used for assessing subjective and objective symptoms prior to and 12 months after administration...
January 19, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28075168/transurethral-resection-of-prostate-and-bleeding-a-prospective-randomized-double-blind-placebo-controlled-trial-to-see-efficacy-of-short-term-use-of-finasteride-and-dutasteride-on-operative-blood-loss-and-prostatic-micro-vessel-density
#13
Ankur Bansal, Aditi Arora
OBJECTIVE: To evaluate the effects of short term use of finasteride and dutasteride on the amount of intraoperative blood loss and microvessel density (MVD) of prostatic stromal and suburethral tissues in the patients with benign prostatic hyperplasia (BPH) prior to transurethral resection of prostate (TURP). METHODS: The study involved 450 male patients who planned to have TURP and were prospectively randomized into 3 groups (150 patients each). Group 1 received placebo, group 2 received finasteride 5 mg/day and group 3 received dutasteride 0...
January 11, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28061966/new-treatments-for-hair-loss
#14
S Vañó-Galván, F Camacho
The treatment of hair loss is an important part of clinical dermatology given the prevalence of the problem and great impact on patients' quality of life. Many new treatments have been introduced in recent years. This review summarizes the main ones in 4 groups: a) For androgenetic alopecia, we discuss new excipients for oral minoxidil, dutasteride, and finasteride as well as new forms of topical application; prostaglandin agonists and antagonists; low-level laser therapy; and regenerative medicine with Wnt signaling activators and stem cell therapy...
January 3, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28024967/extent-of-baseline-prostate-atrophy-is-associated-with-lower-incidence-of-low-and-high-grade-prostate-cancer-on-repeat-biopsy
#15
Daniel M Freitas, Gerald L Andriole, Ramiro Castro-Santamaria, Stephen J Freedland, Daniel M Moreira
OBJECTIVE: To evaluate whether baseline prostate atrophy (PA) extent is associated with prostate cancer (PCa) incidence at 2-year repeat prostate biopsy in a clinical trial with systematic biopsies. MATERIALS AND METHODS: We performed a retrospective analysis of 3165 men 50-75 years old with prostate-specific antigen between 2.5 and 10 ng/mL and a prior negative biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events trial who underwent a 2-year repeat biopsy...
December 23, 2016: Urology
https://www.readbyqxmd.com/read/28006778/a-systematic-review-and-meta-analysis-of-the-effects-on-dutasteride-treatment-for-reducing-surgical-blood-loss-during-transurethral-resection-of-the-prostate
#16
Jian Ren, Shicong Lai, Zhaoqiang Jiang, Xin Xu, Tongxiang Diao, Nikesh Thiruchelvam, Guan Zhang
OBJECTIVE: This systematic review and meta-analysis were performed to evaluate the efficacy of preoperative dutasteride treatment for reducing surgical blood loss in patients undergoing transurethral resection of the prostate (TURP). METHODS: A systematic search was performed from the electronic databases including PubMed, EMBASE, and Cochrane Library by May 2016. We followed the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analysis statement when examining the literature...
December 23, 2016: Urologia Internationalis
https://www.readbyqxmd.com/read/28004415/serum-cholesterol-and-risk-of-lower-urinary-tract-symptoms-progression-results-from-the-reduction-by-dutasteride-of-prostate-cancer-events-study
#17
Tom Feng, Lauren E Howard, Adriana C Vidal, Daniel M Moreira, Ramiro Castro-Santamaria, Gerald L Andriole, Stephen J Freedland
OBJECTIVE: To determine if cholesterol is a risk factor for the development of lower urinary tract symptoms in asymptomatic men. METHODS: A post-hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was carried out in 2323 men with baseline International Prostate Symptom Score <8 and not taking benign prostatic hyperplasia or cholesterol medications. Cox proportion models were used to test the association between cholesterol, high-density lipoprotein, low-density lipoprotein and the cholesterol : high-density lipoprotein ratio with incident lower urinary tract symptoms, defined as first report of medical treatment, surgery or two reports of an International Prostate Symptom Score >14...
December 22, 2016: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/27990661/association-of-obesity-related-hemodilution-of-prostate-specific-antigen-dihydrotestosterone-and-testosterone
#18
Zachary Klaassen, Lauren E Howard, Daniel M Moreira, Gerald L Andriole, Martha K Terris, Stephen J Freedland
BACKGROUND: Prostate-specific antigen (PSA) hemodilution is the leading theory for lower PSA values in obese men. However, testosterone and dihydrotestosterone (DHT), which are necessary for PSA production, are reduced in obese men. We assessed the relationship of body mass index (BMI) and PSA, taking into consideration the effect of testosterone and DHT. METHODS: Among 8,122 participants in Reduction by Dutasteride of Prostate Cancer Events (REDUCE), complete data were available for 7,275...
December 19, 2016: Prostate
https://www.readbyqxmd.com/read/27981373/-combined-treatment-of-bps-with-tamsulosin-and-finasteride-literature-review-and-prescription-data
#19
K Höfner, S Ulrich, R Berges
Combined therapy of benign prostatic syndrome (BPS) with α1-blockers and 5α-reductase (5AR)-inhibitors is recommended according to two leading studies on doxazosin/finasteride and tamsulosin/dutasteride for all 10 in Germany possible combinations (five α1-blockers and two 5AR inhibitors). Because tamsulosin and finasteride predominate in the treatment of BPS in Germany, the role of the combination tamsulosin/finasteride and its scientific basis from clinical studies has been investigated. A pharmacoepidemiological extrapolation from receipts of pharmacy data centres showed a strong increase of the combination tamsulosin/finasteride since 2003...
December 15, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27971355/cost-effectiveness-of-combination-therapy-with-dutasteride-tamsulosin-an-analysis-based-on-conduct-trial
#20
L A Vallejo-Aparicio, B Miñana López, F J Brenes, J M Molero, A Fernández-Pro, A Huerta, J M Cozar
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
43774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"